Supplement
Boswellia + Celery Seed Extract (RestorCel)
Knee osteoarthritis pain and stiffness in one industry-funded 90-day trial; not yet replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away..
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
This product combines boswellia, a tree resin, with celery seed extract. In one 90-day study, people with knee arthritis reported less pain and stiffness. The company that sells the ingredient paid for the study, and no one has repeated it yet. This record covers the combination only, and boswellia alone has its own page.
- Dose studied
- 300 mg + 250 mg/day for 90 days
- Form graded
- RestorCel combination (in Cartigenix HP)
- Cited PMIDs PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed.
- PMID 39875757 →
A letter describes the human evidence, not the product, the manufacturer, or the ingredient's worth.
See the full evidence record →Boswellia + Celery Seed Extract (RestorCel) for knee osteoarthritis pain and stiffness, graded on human trial evidence.
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
This record grades the two-ingredient combination as studied, not Boswellia alone. Boswellia serrata alone holds its own Grade B on meta-analyses A study that pools the numbers from several trials into one combined estimate. of several trials. The combination has one randomized trial, sponsored by the company that sells the ingredient, with self-reported pain and stiffness as the clinical outcomes and inflammatory and cartilage markers as surrogates. That is a single positive trial nobody has independently repeated, which is Grade C by definition. A second trial by an independent group would move it.
WHAT THIS GRADE DOES NOT COVERboswellia alone, which carries its own letter; celery seed alone, which has no graded trial here; any other product combining the two at unknown amounts; and cartilage regeneration, which the trial inferred from blood and urine markers rather than measured in the joint.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Cartigenix HP is sold as one capsule twice daily without per-ingredient amounts on its product page, so a match to the studied amounts cannot be confirmed from the label.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
How this letter has changed · latest: September 2026 · Added
New record for the two-ingredient combination as studied, separate from Boswellia serrata alone, which holds its own Grade B. One randomized, placebo-controlled trial of 62 adults with knee osteoarthritis (Vaidya et al., Pharm Res 2025; PMID 39875757) found less pain and stiffness over 90 days. The trial was funded by the company that sells the ingredient and has not been repeated by an independent group, so the record holds at C.PMID 39875757
Every change to a letter on this site is dated and published. The full evidence log →
Commercial disclosure
EBL earns no commission on any supplement it grades. Grades are assigned by published rubric before any commercial relationship exists and are never influenced by one. Full disclosure.
Boswellia serrata gum resin 300 mg plus celery seed extract 250 mg a day, as studied, for 90 days
Graded as the specific combination tested (RestorCel, sold in Calroy’s Cartigenix HP, directions one capsule twice daily). The Cartigenix HP product page does not list per-ingredient amounts, so whether a serving matches the 300 mg plus 250 mg studied cannot be confirmed from the page. The two other studies on Calroy’s page are described there as observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other., and neither could be found in PubMed; they do not enter the grade. Other boswellia and celery products are not this intervention.
In the cited trial, one capsule was taken twice a day, 30 minutes after breakfast and 30 minutes after dinner (PMID 39875757).
Checked against the full published report. What the cited trials did, not a schedule. Every supplement, by trial timing →
Pregnancy and breastfeeding: not studied. Boswellia carries a mechanistic bleeding caution; see the Boswellia serrata record.
Boswellic acids inhibit 5-lipoxygenase and show antiplatelet activity in laboratory work, so anticoagulants and antiplatelets are a mechanistic caution rather than a measured one. Celery (Apium graveolens) is discussed in reviews as possibly additive with blood-pressure medication; no human interaction study of celery seed extract, alone or in this combination, was found.
Mechanism-based, no human interaction study located. The interaction cautions for the boswellia and celery seed combination rest on pharmacology, not on a study in people. Boswellia's antiplatelet caution is laboratory work, covered on the Boswellia serrata record. For celery, PubMed returned 7 records in September 2026; they are reviews and laboratory or computer-model studies, including two reviews that list celery among herbs that could add to blood-pressure medication. No study gave celery seed extract with a drug and measured the result, and no study at all has tested the two-ingredient combination for interactions. Basis: pharmacological mechanism, not a human study. Searched PubMed in September 2026: 2 queries, 7 human results.
WOMAC or VAS knee pain and stiffness at baseline, 6 weeks and 90 days, matching the trial. hs-CRP High-sensitivity C-reactive protein, a blood marker of low-grade inflammation. if available, since the trial reported inflammatory markers falling.
Primary evidenceOne paper, linked to its PubMed record.
Vaidya et al. (Pharm Res, 2025; PMID 39875757): randomized, double-blind, placebo-controlled, multicenter trial in 62 adults with knee osteoarthritis. The combination of a standardized Boswellia serrata gum resin (300 mg) and Apium graveolens (celery) seed extract (250 mg) for 90 days reduced pain, stiffness and swelling on WOMAC and VAS compared with placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received., and lowered inflammatory and cartilage-breakdown markers. No adverse effects were reported. The trial was funded by Phytoveda, which markets the combination as RestorCel; RestorCel is the active ingredient in Calroy’s Cartigenix HP. Grade C: one industry-funded trial of 62 people on self-reported outcomes, not yet repeated by an independent group.
Educational use only · Not medical advice · Starting, stopping or changing any supplement or medication is a decision for your physician
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →